Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Amini, Afshina | Heidari, Kamranb | Asadollahi, Shadic; * | Habibi, Tahereha | Shahrami, Alia | Mansouri, Behnamd | Kariman, Hamidrezaa
Affiliations: [a] Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [b] Department of Emergency Medicine, Shohadaye-Haftom Tir Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [c] School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [d] Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Correspondence: [*] Corresponding author: Shadi Asadollahi, School of Medicine, Shahid Beheshti University of Medical Sciences, Daneshju Blvd, Evin, Tehran, Iran. Tel.: +98 912 770 91 49; Fax: +98 21 552 037 97; E-mail: asadollahi.shadi@yahoo.com; shasadollahi@sbmu.ac.ir
Abstract: Background:Vertigo imposes considerable health restrictions with significant impact on the patient's quality of life. The most effective antivertigo agent is undetermined thus far. Objective:This study was performed to assess whether promethazine has superior vertigo reduction compared with lorazepam in ED patients. Methods:In this randomized, double-blind, parallel group trial 184 patients were assigned (1:1 ratio) to receive either promethazine, 25 mg intravenously, or lorazepam, 2 mg intravenously. Primary endpoint was mean change in vertigo intensity at 2 hours measured using visual analog scale (VAS). Secondary endpoints were mean change in nausea score, need for second dose of study medications, and adverse events (AEs). Results:Promethazine was associated with significantly more reduction (46.5 mm) in vertigo than lorazepam (25.7 mm, p< 0.001). Mean change in nausea score 2 hours after drug injection on the VAS was 28.7 mm for promethazine and 22.8 for lorazepam (p=0.002). The most frequently reported AEs were lethargy (14.1% in lorazepam group, 4.3% in promethazine group, p=0.013) and drowsiness (10.8% for promethazine, 2.1% for lorazepam, p=0.017). Conclusion:Our study demonstrated the evidence that promethazine is superior to lorazepam in management of peripheral vertigo and vertigo-related nausea in ED adults.
Keywords: Vertigo, nausea, promethazine, lorazepam, clinical trial
DOI: 10.3233/VES-130506
Journal: Journal of Vestibular Research, vol. 24, no. 1, pp. 39-47, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl